speb/financial-data huggingface dataset:
Financial ratios for QEC.OL — quarterly report dated 2025-12-31
Total revenue: 31043795.620437954
Gross profit: -5577372.262773722
Operating income: -11243795.620437955
Net income: -53232116.78832117
Capital expenditures: 3255474.452554744
Operating cash flow: 1224817.518248175
Depreciation & amortization: 11319708.02919708
Net tangible assets: 18427737.22627737
Owner earnings: -45167883.21167883
Return on net tangible assets (%): -245.10813594232755
Buffett classification: The Gruesome
Stock price: 0.22709163346613545
Shares outstanding: 452213454
Book value: 55955474.4525547
P/B ratio: 1.8352787273977713
Market cap (USD): 102693891.9442231
Debt to equity: 1.3335420498571606
Current ratio: 0.498112041409547
Quick ratio: 0.412125426118531
COGS to revenue (%): 117.96614154714318
SG&A to revenue (%): 11.42722783917235
Free cash flow (dilution-adjusted): -2140145.9854014595
Buyback yield (%): 0
Retained earnings: -292235766.42335767
Inventory turnover: 5.634658580413297
Receivables turnover: 3.8109318996415773
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -5.280568782116547
FCF margin (%): -6.89395720667764
Revenue growth (%): 265.6544014270719
Rule of 40 score: 258.7604442203943
Financial ratios for RBX.AX — annual report dated 2022-06-30
Operating income: -1508893.103448276
Net income: -1510542.0689655172
Capital expenditures: 225539.3103448276
Depreciation & amortization: 4633.103448275862
Net tangible assets: 4861049.655172414
Owner earnings: -1731448.2758620689
Return on net tangible assets (%): -35.61881483806108
Buffett classification: The Gruesome
Stock price: 0.08965517241379312
Shares outstanding: 115184486
Book value: 4861049.655172413
P/B ratio: 2.1244146191215694
Market cap (USD): 10326884.95172414
Debt to equity: 0.00806892565561972
Current ratio: 7.820944376627164
Quick ratio: 7.820944376627164
Interest coverage ratio: -234.42569377477767
Free cash flow (dilution-adjusted): -2843377.931034483
Buyback yield (%): 2.6349101321749977
Retained earnings: -14750927.586206896
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -30.834370473010388
Rule of 40 score: 0
Financial ratios for RBX.AX — annual report dated 2023-06-30
Operating income: -2712218.5430463576
Net income: -2672718.5430463576
Capital expenditures: 45828.47682119205
Depreciation & amortization: 37436.4238410596
Net tangible assets: 3884755.6291390727
Owner earnings: -2681110.59602649
Return on net tangible assets (%): -69.0161969498367
Buffett classification: The Gruesome
Stock price: 0.11920529801324503
Shares outstanding: 115184486
Book value: 3884755.6291390727
P/B ratio: 3.534482549466151
Market cap (USD): 13730600.98013245
Debt to equity: 0
Current ratio: 25.253033409907342
Quick ratio: 25.253033409907342
Interest coverage ratio: -191.49249544115585
Free cash flow (dilution-adjusted): -1661516.5562913907
Buyback yield (%): 0.591881406282054
Retained earnings: -16837516.55629139
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -69.8169666761621
Rule of 40 score: 0
Financial ratios for REZ.AX — annual report dated 2021-06-30
Operating income: -1102759.3984962406
Net income: -1106909.7744360901
Capital expenditures: 297744.36090225563
Depreciation & amortization: 781.9548872180451
Net tangible assets: 5142121.052631578
Owner earnings: -1403872.1804511277
Return on net tangible assets (%): -27.30142223572643
Buffett classification: The Gruesome
Stock price: 0.022556390977443608
Shares outstanding: 929277346
Book value: 6920415.7894736845
P/B ratio: 3.028884937049612
Market cap (USD): 20961143.14285714
Debt to equity: 0
Current ratio: 3.1660674842391052
Quick ratio: 3.1660674842391052
Interest coverage ratio: -252.74340858176808
Free cash flow (dilution-adjusted): -2770835.3383458643
Buyback yield (%): 0.8548291172195792
Retained earnings: -21288241.35338346
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -15.089118359564162
Rule of 40 score: 0
Financial ratios for REZ.AX — annual report dated 2022-06-30
Operating income: -2200669.6551724137
Net income: 112958.62068965517
Capital expenditures: 1381740.6896551724
Depreciation & amortization: 920
Net tangible assets: 7152666.206896552
Owner earnings: -1267862.0689655172
Return on net tangible assets (%): -17.725726775045832
Buffett classification: The Gruesome
Stock price: 0.020689655172413793
P/E ratio: 170.20770730813845
Shares outstanding: 929277346
Book value: 8782664.827586208
P/B ratio: 2.1891337339762713
Market cap (USD): 19226427.848275863
Debt to equity: 0
Current ratio: 6.204749521468109
Quick ratio: 6.204749521468109
Effective tax rate (%): 0
Interest coverage ratio: -797742.7499999999
Free cash flow (dilution-adjusted): 195271.03448275864
Buyback yield (%): 0.6648535402189104
Retained earnings: -19413497.24137931
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -24.402321231680695
Rule of 40 score: 0
Financial ratios for REZ.AX — annual report dated 2023-06-30
Operating income: -882874.1721854304
Net income: -882303.9735099338
Capital expenditures: 20377.48344370861
Depreciation & amortization: 883.4437086092715
Net tangible assets: 4847988.079470199
Owner earnings: -901798.0132450331
Return on net tangible assets (%): -18.601489905964954
Buffett classification: The Gruesome
Stock price: 0.013245033112582781
Shares outstanding: 929277346
Book value: 6412697.350993377
P/B ratio: 1.9193653691821886
Market cap (USD): 12308309.218543047
Debt to equity: 0
Current ratio: 3.1360875687302054
Quick ratio: 3.1360875687302054
Free cash flow (dilution-adjusted): -2075667.5496688741
Buyback yield (%): 0
Retained earnings: -20707817.218543045
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -13.247565431678707
Rule of 40 score: 0
Financial ratios for REZ.AX — annual report dated 2024-06-30
Operating income: -1015384.6666666666
Net income: -830722.6666666666
Capital expenditures: 1575.3333333333333
Depreciation & amortization: 1178
Net tangible assets: 5315293.333333333
Owner earnings: -831120
Return on net tangible assets (%): -15.636390089477658
Buffett classification: The Gruesome
Stock price: 0.006666666666666667
Shares outstanding: 929277346
Book value: 6889566.666666667
P/B ratio: 0.8992121865429369
Market cap (USD): 6195182.306666667
Debt to equity: 0
Current ratio: 0.9436361221036733
Quick ratio: 0.9436361221036733
Free cash flow (dilution-adjusted): -720162
Buyback yield (%): 0.8289559659619639
Retained earnings: -21675724
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -14.28050921552587
Rule of 40 score: 0
Financial ratios for RSVR — annual report dated 2022-03-31
Total revenue: 107840245
Gross profit: 63654408
Operating income: 19353021
Net income: 13128397
Capital expenditures: 202774
Operating cash flow: 12478566
Depreciation & amortization: 19022131
Net tangible assets: -225391065
Owner earnings: 31947754
Return on net tangible assets (%): -14.17436578508558
Capex to operating income (%): 1.0477640674290591
Buffett classification: The Great
Stock price: 9.83
P/E ratio: 49.279043301326126
Shares outstanding: 65814328
Book value: 347452324
P/B ratio: 1.8619960194596368
Market cap (USD): 646954844.24
Debt to equity: 0.7766710721439871
Current ratio: 1.4475208387840712
Quick ratio: 1.3491038645870124
Effective tax rate (%): 24.469523471070453
Interest coverage ratio: 1.780264884140785
COGS to revenue (%): 40.97342045170613
SG&A to revenue (%): 23.441393331404246
Free cash flow (dilution-adjusted): -184770615
Buyback yield (%): 0
Retained earnings: 12213519
Inventory turnover: 10.933107524463246
Receivables turnover: 4.2775184943549895
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.008840346738802
FCF margin (%): -171.33734720279986
Rule of 40 score: -171.33734720279986
Financial ratios for RSVR — annual report dated 2023-03-31
Total revenue: 122286530
Gross profit: 74300400
Operating income: 21057717
Net income: 2779633
Capital expenditures: 406402
Operating cash flow: 31203724
Depreciation & amortization: 22074897
Net tangible assets: -269442184
Owner earnings: 24448128
Return on net tangible assets (%): -9.07360816226163
Capex to operating income (%): 1.9299433077194457
Buffett classification: The Great
Stock price: 6.52
P/E ratio: 154.37628584780794
Shares outstanding: 65814328
Book value: 349662523
P/B ratio: 1.2272102108008869
Market cap (USD): 429109418.55999994
Debt to equity: 0.91106170391615
Current ratio: 1.2247564773101187
Quick ratio: 1.1246839068848697
Effective tax rate (%): 66.92696283158759
Interest coverage ratio: 1.4270432463345715
COGS to revenue (%): 39.240732401189234
SG&A to revenue (%): 25.4875054513363
Free cash flow (dilution-adjusted): -44230064
Buyback yield (%): 0
Retained earnings: 14752720
Inventory turnover: 8.791048199494295
Receivables turnover: 3.912434423911517
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.0102350812053134
FCF margin (%): -36.16920359094334
Revenue growth (%): 13.396005359594648
Rule of 40 score: -22.773198231348694
Financial ratios for RSVR — annual report dated 2024-03-31
Total revenue: 144855690
Gross profit: 89377404
Operating income: 24575824
Net income: 837261
Capital expenditures: 225677
Operating cash flow: 36192550
Depreciation & amortization: 24985688
Net tangible assets: -287629309
Owner earnings: 25597272
Return on net tangible assets (%): -8.899396271191543
Capex to operating income (%): 0.9182886400879173
Buffett classification: The Great
Stock price: 7.93
P/E ratio: 623.3511665299112
Shares outstanding: 65814328
Book value: 354484981
P/B ratio: 1.4722982608958544
Market cap (USD): 521907621.03999996
Debt to equity: 0.952119023626561
Current ratio: 1.174530370520355
Quick ratio: 1.0701615738887713
Effective tax rate (%): 28.565309944414345
Interest coverage ratio: 1.165409639252962
COGS to revenue (%): 38.299003649770334
SG&A to revenue (%): 27.486591655460686
Free cash flow (dilution-adjusted): -17547295
Buyback yield (%): 0
Retained earnings: 15397657
Inventory turnover: 8.80479835071573
Receivables turnover: 4.359527632962476
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.3983799379805597
FCF margin (%): -12.113638753161855
Revenue growth (%): 18.455965673406546
Rule of 40 score: 6.342326920244691
Financial ratios for RSVR — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 8.11
Shares outstanding: 65814328
Market cap (USD): 533754200.08
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for RSVR — quarterly report dated 2024-12-31
Total revenue: 42303716
Gross profit: 27235716
Operating income: 9557999
Net income: 5311539
Capital expenditures: 1639
Operating cash flow: 11233261
Depreciation & amortization: 6713621
Net tangible assets: -333915718
Owner earnings: 12023521
Return on net tangible assets (%): -3.600765208662624
Capex to operating income (%): 0.01714794069344431
Buffett classification: The Great
Stock price: 9.05
P/E ratio: 28.034232093560835
Shares outstanding: 65814328
Book value: 360782944
P/B ratio: 1.6509086094712948
Market cap (USD): 595619668.4000001
Debt to equity: 1.0469340618274905
Current ratio: 1.1989057003596277
Quick ratio: 1.0713734140160793
Effective tax rate (%): 27.226122389925095
Interest coverage ratio: 1.6545315873101327
COGS to revenue (%): 35.6186203594975
SG&A to revenue (%): 25.917571874773365
Free cash flow (dilution-adjusted): -49429068
Buyback yield (%): 0
Retained earnings: 20480108
Inventory turnover: 1.9142745962624894
Receivables turnover: 1.2200914157553726
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 1.2402587079240615
FCF margin (%): -116.84332411838241
Rule of 40 score: -116.84332411838241
Financial ratios for RSVR — quarterly report dated 2025-03-31
Total revenue: 41417784
Gross profit: 27168779
Operating income: 10419989
Net income: 2721046
Capital expenditures: 24668
Operating cash flow: 12174691
Depreciation & amortization: 6770836
Net tangible assets: -354795443
Owner earnings: 9467214
Return on net tangible assets (%): -2.668358398278526
Capex to operating income (%): 0.2367372940604832
Buffett classification: The Great
Stock price: 7.63
P/E ratio: 46.13697477367159
Shares outstanding: 65814328
Book value: 366199782
P/B ratio: 1.3712824182948313
Market cap (USD): 502163322.64
Debt to equity: 1.0755295425052984
Current ratio: 1.2042467234203518
Quick ratio: 1.130320779488184
Effective tax rate (%): 18.069927534813672
Interest coverage ratio: 1.7119404191531176
COGS to revenue (%): 34.40310809482226
SG&A to revenue (%): 24.09098951310384
Free cash flow (dilution-adjusted): -15183258
Buyback yield (%): 0
Retained earnings: 23147570
Inventory turnover: 2.9276284902593566
Receivables turnover: 1.0943012941743093
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 1.3036560140684301
FCF margin (%): -36.658788891264685
Revenue growth (%): -2.094217916931931
Rule of 40 score: -38.753006808196616
Financial ratios for RSVR — annual report dated 2025-03-31
Total revenue: 158705736
Gross profit: 101275731
Operating income: 35061034
Net income: 7749913
Capital expenditures: 81538
Operating cash flow: 45279489
Depreciation & amortization: 26299233
Net tangible assets: -354795443
Owner earnings: 33967608
Return on net tangible assets (%): -9.573856899847499
Capex to operating income (%): 0.2325601692180556
Buffett classification: The Great
Stock price: 7.63
P/E ratio: 64.7959948247161
Shares outstanding: 65814328
Book value: 366199782
P/B ratio: 1.3712824182948313
Market cap (USD): 502163322.64
Debt to equity: 1.0755295425052984
Current ratio: 1.2042467234203518
Quick ratio: 1.130320779488184
Effective tax rate (%): 21.684539725556444
Interest coverage ratio: 1.6021806744963436
COGS to revenue (%): 36.186470916211874
SG&A to revenue (%): 25.15061207365561
Free cash flow (dilution-adjusted): -55669860
Buyback yield (%): 0
Retained earnings: 23147570
Inventory turnover: 11.799681369592985
Receivables turnover: 4.193172003062411
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 4.3865236166331565
FCF margin (%): -35.07740892238451
Revenue growth (%): 9.561271635239182
Rule of 40 score: -25.516137287145327
Financial ratios for RSVR — quarterly report dated 2025-06-30
Total revenue: 37164293
Gross profit: 23971293
Operating income: 5446409
Net income: -555659
Capital expenditures: 33608
Operating cash flow: 6014143
Depreciation & amortization: 7313737
Net tangible assets: -352921378
Owner earnings: 6724470
Capex to operating income (%): 0.6170671354281325
Buffett classification: The Great
Stock price: 7.67
P/E ratio: 67.51382797689853
Shares outstanding: 65814328
Book value: 370108501
P/B ratio: 1.3639132697468086
Market cap (USD): 504795895.76
Debt to equity: 1.061468128774486
Current ratio: 1.293643111431956
Quick ratio: 1.293643111431956
Interest coverage ratio: 0.8650643794002437
COGS to revenue (%): 35.49912815508154
SG&A to revenue (%): 30.1664476706176
Free cash flow (dilution-adjusted): -3091963
Buyback yield (%): 0
Retained earnings: 22591911
Receivables turnover: 1.0718022848958022
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 0.6780267016069609
FCF margin (%): -8.319714302112514
Revenue growth (%): -10.269721335163657
Rule of 40 score: -18.58943563727617
Financial ratios for RSVR — quarterly report dated 2025-09-30
Total revenue: 45435051
Gross profit: 28902051
Operating income: 10685746
Net income: 2257841
Capital expenditures: 125541
Operating cash flow: 19290697
Depreciation & amortization: 7556863
Net tangible assets: -381534736
Owner earnings: 9689163
Return on net tangible assets (%): -2.5395231641503804
Capex to operating income (%): 1.1748454436405282
Buffett classification: The Great
Stock price: 8.14
P/E ratio: 55.03250667632826
Shares outstanding: 65814328
Book value: 372116491
P/B ratio: 1.4396798929290129
Market cap (USD): 535728629.92
Debt to equity: 1.1514171566236768
Current ratio: 1.3524771584495585
Quick ratio: 1.3524771584495585
Effective tax rate (%): 30.062272128216545
Interest coverage ratio: 1.5850325817525277
COGS to revenue (%): 36.388206101056205
SG&A to revenue (%): 23.460834235665324
Free cash flow (dilution-adjusted): -22132343
Buyback yield (%): 0
Retained earnings: 24849752
Receivables turnover: 1.2662076981272827
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 1.2697147551746457
FCF margin (%): -48.71204612491796
Revenue growth (%): 22.254581837464258
Rule of 40 score: -26.457464287453703
Financial ratios for RSVR — quarterly report dated 2025-12-31
Total revenue: 45567879
Gross profit: 29369879
Operating income: 10327414
Net income: 2203030
Capital expenditures: 128378
Operating cash flow: 12924743
Depreciation & amortization: 7789274
Net tangible assets: -423554492
Owner earnings: 9863926
Return on net tangible assets (%): -2.32884462006839
Capex to operating income (%): 1.2430798261791383
Buffett classification: The Great
Stock price: 7.57
P/E ratio: 75.18790589801966
Shares outstanding: 65814328
Book value: 374800652
P/B ratio: 1.3292785386083055
Market cap (USD): 498214462.96000004
Debt to equity: 1.2258619496745167
Current ratio: 1.1860540121317025
Quick ratio: 1.1860540121317025
Effective tax rate (%): 32.86408926790856
Interest coverage ratio: 1.568559175080608
COGS to revenue (%): 35.54696939043399
SG&A to revenue (%): 24.695446105797465
Free cash flow (dilution-adjusted): -38067913
Buyback yield (%): 0
Retained earnings: 27045737
Receivables turnover: 1.2297242642043473
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 1.1785575689825531
FCF margin (%): -83.5411123699657
Revenue growth (%): 0.2923469811885982
Rule of 40 score: -83.2487653887771
Financial ratios for SFSN.SW — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 124.76923076923077
Shares outstanding: 38875443
Market cap (USD): 4850459118.923077
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SFSN.SW — annual report dated 2022-12-31
Total revenue: 2998478260.869565
Gross profit: 1730869565.2173913
Operating income: 355978260.8695652
Net income: 294130434.7826087
Capital expenditures: 160869565.2173913
Operating cash flow: 312934782.6086956
Depreciation & amortization: 128043478.26086956
Net tangible assets: 1333695652.173913
Owner earnings: 261304347.82608694
Return on net tangible assets (%): 19.592502037489812
Capex to operating income (%): 45.19083969465649
Buffett classification: The Good
Stock price: 87.14130434782608
P/E ratio: 11.517532392128603
Shares outstanding: 38875443
Book value: 1416956521.7391305
P/B ratio: 2.3907979942543722
Market cap (USD): 3387656810.119565
Debt to equity: 0.5363608468855476
Current ratio: 2.796831127156037
Quick ratio: 1.5320898515844363
Effective tax rate (%): 19.893428063943162
Interest coverage ratio: 34.84042553191489
COGS to revenue (%): 42.27506706300297
SG&A to revenue (%): 5.549916624374683
Free cash flow (dilution-adjusted): 127065217.39130434
Buyback yield (%): 0
Retained earnings: 1198369565.2173913
Inventory turnover: 1.8493498255629557
Receivables turnover: 6.684274291252725
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 15.778570052033148
FCF margin (%): 4.237656782425868
Rule of 40 score: 4.237656782425868
Financial ratios for SFSN.SW — annual report dated 2023-12-31
Total revenue: 3678928571.4285717
Gross profit: 2091428571.4285715
Operating income: 421785714.2857143
Net income: 319642857.14285713
Capital expenditures: 187619047.6190476
Operating cash flow: 373095238.0952381
Depreciation & amortization: 151666666.6666667
Net tangible assets: 1545238095.2380953
Owner earnings: 283690476.1904762
Return on net tangible assets (%): 18.359013867488443
Capex to operating income (%): 44.4820773355913
Buffett classification: The Good
Stock price: 116.11904761904763
P/E ratio: 14.122572477541901
Shares outstanding: 38875443
Book value: 1637738095.238095
P/B ratio: 2.7563500110634593
Market cap (USD): 4514179416.928572
Debt to equity: 0.4890601148506216
Current ratio: 3.072578816058063
Quick ratio: 1.823089135858471
Effective tax rate (%): 23.764906303236796
Interest coverage ratio: 17.62686567164179
COGS to revenue (%): 43.15115037375012
SG&A to revenue (%): 5.54315115037375
Free cash flow (dilution-adjusted): 165952380.95238096
Buyback yield (%): 0
Retained earnings: 1456904761.904762
Inventory turnover: 2.4205844980940276
Receivables turnover: 6.740021810250818
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 16.82416069139086
FCF margin (%): 4.510888910461768
Revenue growth (%): 22.693188056053295
Rule of 40 score: 27.20407696651506
Financial ratios for SFSN.SW — quarterly report dated 2024-12-31
Capital expenditures: 0
Net tangible assets: 1640111111.1111112
Buffett classification: The Gruesome
Stock price: 133.65555555555557
Shares outstanding: 38875443
Book value: 1732444444.4444442
P/B ratio: 2.9991835803424842
Market cap (USD): 5195918931.633334
Debt to equity: 0.3589020010261673
Current ratio: 2.05706642888988
Quick ratio: 1.2361420716302571
Buyback yield (%): 0
Retained earnings: 1621111111.1111112
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SFSN.SW — annual report dated 2024-12-31
Total revenue: 3389000000
Gross profit: 1968111111.1111112
Operating income: 385888888.8888889
Net income: 269666666.6666667
Capital expenditures: 152333333.33333334
Operating cash flow: 416666666.6666666
Depreciation & amortization: 144000000
Net tangible assets: 1640111111.1111112
Owner earnings: 261333333.33333334
Return on net tangible assets (%): 15.933879818440486
Capex to operating income (%): 39.47595738554564
Buffett classification: The Good
Stock price: 133.65555555555557
P/E ratio: 19.26793176131026
Shares outstanding: 38875443
Book value: 1732444444.4444442
P/B ratio: 2.9991835803424842
Market cap (USD): 5195918931.633334
Debt to equity: 0.3589020010261673
Current ratio: 2.05706642888988
Quick ratio: 1.2361420716302571
Effective tax rate (%): 25.620594544897337
Interest coverage ratio: 18.47340425531915
COGS to revenue (%): 41.92649421330448
R&D to revenue (%): 2.491721582898921
SG&A to revenue (%): 5.4293301858955445
Free cash flow (dilution-adjusted): 251222222.2222222
Buyback yield (%): 0
Retained earnings: 1621111111.1111112
Inventory turnover: 2.3149891383055756
Receivables turnover: 6.511742100768574
Capitalized R&D asset: 84444444.44444445
ROCI (R&D-adjusted, %): 19.747266742751286
FCF margin (%): 7.412871709124291
Revenue growth (%): -7.880788272983212
Rule of 40 score: -0.4679165638589211
Financial ratios for SFSN.SW — quarterly report dated 2025-06-30
Capital expenditures: 0
Net tangible assets: 1783500000
Buffett classification: The Gruesome
Stock price: 133.21249999999998
Shares outstanding: 38875443
Book value: 1878500000
P/B ratio: 2.7568245678134145
Market cap (USD): 5178694950.637499
Debt to equity: 0.3231966994942774
Current ratio: 2.792289867284601
Quick ratio: 1.6376658942489994
Buyback yield (%): 0
Retained earnings: 1815125000
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SORA — quarterly report dated 2025-06-30
Capital expenditures: 0
Net tangible assets: 1137615.6687898089
Buffett classification: The Gruesome
Stock price: 6.38
Shares outstanding: 24864000
Book value: 1137615.668789809
P/B ratio: 139.44280511603046
Market cap (USD): 158632320
Debt to equity: 0.5817983595816616
Current ratio: 5.847816960353389
Quick ratio: 4.391568466766875
Buyback yield (%): 0
Retained earnings: -153060.7643312102
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SQZ.L — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 0.020675675675675676
Shares outstanding: 390554624
Market cap (USD): 8074980.73945946
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SQZ.L — annual report dated 2022-12-31
Total revenue: 1184571034.5542169
Gross profit: 866485389.4698795
Operating income: 847647102.313253
Net income: 259239326.8795181
Capital expenditures: 141577309.95180723
Operating cash flow: 816724316.3975904
Depreciation & amortization: 112106763.51807229
Net tangible assets: 595343373.4939759
Owner earnings: 229768780.44578317
Return on net tangible assets (%): 38.59432903356371
Capex to operating income (%): 16.702388242163362
Buffett classification: The Great
Stock price: 0.023012048192771084
P/E ratio: 0.03466858959086299
Shares outstanding: 390554624
Book value: 595343373.4939759
P/B ratio: 0.01509626583504508
Market cap (USD): 8987461.82939759
Debt to equity: 0
Current ratio: 2.4227321065596943
Quick ratio: 2.406449385996204
Effective tax rate (%): 63.57967790400822
Interest coverage ratio: 619.7739867023465
COGS to revenue (%): 26.852390934587472
SG&A to revenue (%): 1.1354922252561945
Free cash flow (dilution-adjusted): 670029174.5662651
Buyback yield (%): 0
Retained earnings: 312838554.2168675
Inventory turnover: 54.56603300008907
Receivables turnover: 6.040722032182156
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 94.37935074036214
FCF margin (%): 56.56302197347022
Rule of 40 score: 56.56302197347022
Financial ratios for SQZ.L — annual report dated 2023-12-31
Total revenue: 998632911.392405
Gross profit: 483708860.75949365
Operating income: 481051898.7341772
Net income: 161717721.51898733
Capital expenditures: 123611392.40506329
Operating cash flow: 153568354.43037975
Depreciation & amortization: 172849367.08860758
Net tangible assets: 1055908860.7594936
Owner earnings: 210955696.20253164
Return on net tangible assets (%): 19.97858944481208
Capex to operating income (%): 25.696061637076976
Buffett classification: The Good
Stock price: 0.021645569620253165
P/E ratio: 0.05227489742558138
Shares outstanding: 390554624
Book value: 1055908860.7594936
P/B ratio: 0.008006161912708233
Market cap (USD): 8453777.304303797
Debt to equity: 0.32794353175859065
Current ratio: 2.2076250836515374
Quick ratio: 2.1530645986694488
Effective tax rate (%): 66.41252882054626
Interest coverage ratio: 17.66271611823759
COGS to revenue (%): 51.56289611113928
SG&A to revenue (%): 3.103736754043503
Free cash flow (dilution-adjusted): 23701265.82278481
Buyback yield (%): 0
Retained earnings: 350365822.7848101
Inventory turnover: 29.34992784992785
Receivables turnover: 7.429884537868942
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 28.745345335805233
FCF margin (%): 2.373371190995285
Revenue growth (%): -15.696662989213214
Rule of 40 score: -13.32329179821793
Financial ratios for SQZ.L — quarterly report dated 2024-12-31
Capital expenditures: 0
Net tangible assets: 995572500
Buffett classification: The Gruesome
Stock price: 0.01475
Shares outstanding: 390554624
Book value: 995572500
P/B ratio: 0.005786299545236535
Market cap (USD): 5760680.704
Debt to equity: 0.2816432253803716
Current ratio: 1.9275950324288165
Quick ratio: 1.855446974764661
Buyback yield (%): 0
Retained earnings: 312292500
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SQZ.L — annual report dated 2024-12-31
Total revenue: 908972500
Gross profit: 278996250
Operating income: 284447500
Net income: 115536250
Capital expenditures: 325216250
Operating cash flow: 351953750
Depreciation & amortization: 235400000
Net tangible assets: 995572500
Owner earnings: 25720000
Return on net tangible assets (%): 2.5834381725087825
Capex to operating income (%): 114.33260970829416
Buffett classification: The Gruesome
Stock price: 0.01475
P/E ratio: 0.04986037459238983
Shares outstanding: 390554624
Book value: 995572500
P/B ratio: 0.005786299545236535
Market cap (USD): 5760680.704
Debt to equity: 0.2816432253803716
Current ratio: 1.9275950324288165
Quick ratio: 1.855446974764661
Effective tax rate (%): 42.41112038779299
Interest coverage ratio: 7.290254373037739
COGS to revenue (%): 69.30641466050953
SG&A to revenue (%): 2.8233802452769474
Free cash flow (dilution-adjusted): 22068750
Buyback yield (%): 407.39543130214076
Retained earnings: 312292500
Inventory turnover: 33.86058855146466
Receivables turnover: 12.791844776329446
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 18.082331112356023
FCF margin (%): 2.4278787312047396
Revenue growth (%): -8.978315291791308
Rule of 40 score: -6.550436560586569
Financial ratios for SQZ.L — quarterly report dated 2025-06-30
Capital expenditures: 0
Net tangible assets: 989173972.6027397
Buffett classification: The Gruesome
Stock price: 0.020273972602739727
Shares outstanding: 390554624
Book value: 989173972.6027398
P/B ratio: 0.008004753426755684
Market cap (USD): 7918093.746849315
Debt to equity: 0.31144292248825295
Current ratio: 1.720329698269685
Quick ratio: 1.6454449216203848
Buyback yield (%): 0
Retained earnings: 199309589.04109588
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SSB — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 71.58
Shares outstanding: 96971142
Market cap (USD): 6941194344.36
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SSB — annual report dated 2022-12-31
Total revenue: 1613286000
Net income: 496049000
Capital expenditures: 11527000
Operating cash flow: 1730893000
Depreciation & amortization: 64591000
Net tangible assets: 2948761000
Owner earnings: 549113000
Return on net tangible assets (%): 18.621821164889255
Buffett classification: The Gruesome
Stock price: 69.87
P/E ratio: 13.65867825868009
Shares outstanding: 96971142
Book value: 5074927000
P/B ratio: 1.3350682071958868
Market cap (USD): 6775373691.540001
Debt to equity: 0.0752651220401791
Effective tax rate (%): 21.6800186938907
COGS to revenue (%): 0
SG&A to revenue (%): 37.81239036351893
Free cash flow (dilution-adjusted): 1677585000
Buyback yield (%): 1.7612312683062803
Retained earnings: 1347042000
Capitalized R&D asset: 0
FCF margin (%): 103.98559213927349
Rule of 40 score: 103.98559213927349
Financial ratios for SSB — annual report dated 2023-12-31
Total revenue: 1700638000
Net income: 494308000
Capital expenditures: 38029000
Operating cash flow: 546757000
Depreciation & amortization: 58826000
Net tangible assets: 3436052000
Owner earnings: 515105000
Return on net tangible assets (%): 14.991187560607347
Buffett classification: The Gruesome
Stock price: 79.5
P/E ratio: 15.595955940425808
Shares outstanding: 96971142
Book value: 5533098000
P/B ratio: 1.3932892186258041
Market cap (USD): 7709205789
Debt to equity: 0.08703876200999874
Effective tax rate (%): 21.644379347295402
COGS to revenue (%): 0
SG&A to revenue (%): 40.06972677312867
Free cash flow (dilution-adjusted): 472011000
Buyback yield (%): 0.2083742533234898
Retained earnings: 1685166000
Capitalized R&D asset: 0
FCF margin (%): 27.754936676706038
Revenue growth (%): 5.414539021599394
Rule of 40 score: 33.16947569830543
Financial ratios for SSB — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 93.24
Shares outstanding: 96971142
Market cap (USD): 9041589280.08
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SSB — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 95.93
Shares outstanding: 96971142
Market cap (USD): 9302441652.060001
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SSB — annual report dated 2024-12-31
Total revenue: 1667131000
Net income: 534783000
Capital expenditures: 35434000
Operating cash flow: 511960000
Depreciation & amortization: 56697000
Net tangible assets: 3811056000
Owner earnings: 556046000
Return on net tangible assets (%): 14.590339265547398
Buffett classification: The Gruesome
Stock price: 95.93
P/E ratio: 17.394796865382784
Shares outstanding: 96971142
Book value: 5890415000
P/B ratio: 1.5792506388870735
Market cap (USD): 9302441652.060001
Debt to equity: 0.06471937885530986
Effective tax rate (%): 23.62948555368955
COGS to revenue (%): 0
SG&A to revenue (%): 40.7545057946856
Free cash flow (dilution-adjusted): 448153000
Buyback yield (%): 0.18014625220776292
Retained earnings: 2046809000
Capitalized R&D asset: 0
FCF margin (%): 26.881690760953997
Revenue growth (%): -1.9702605727967977
Rule of 40 score: 24.9114301881572
Financial ratios for SSB — quarterly report dated 2025-03-31
Total revenue: 630635000
Net income: 89080000
Capital expenditures: 11853000
Operating cash flow: -126260000
Depreciation & amortization: 35268000
Net tangible assets: 4993117000
Owner earnings: 112495000
Return on net tangible assets (%): 2.253001481839901
Buffett classification: The Gruesome
Stock price: 89.96
P/E ratio: 24.482274175797038
Shares outstanding: 96971142
Book value: 8624361000
P/B ratio: 1.0114980036573142
Market cap (USD): 8723523934.32
Debt to equity: 0.08728739439362522
Effective tax rate (%): 26.53014095194108
COGS to revenue (%): 0
SG&A to revenue (%): 34.230418546385785
Free cash flow (dilution-adjusted): -147336000
Buyback yield (%): 0.12811336432552783
Retained earnings: 2080053000
Capitalized R&D asset: 0
FCF margin (%): -23.363118126967265
Rule of 40 score: -23.363118126967265
Financial ratios for SSB — quarterly report dated 2025-06-30
Total revenue: 664765000
Net income: 215224000
Capital expenditures: 20108000
Operating cash flow: 72609000
Depreciation & amortization: 39733000
Net tangible assets: 5187781000
Owner earnings: 234849000
Return on net tangible assets (%): 4.526964418891237
Buffett classification: The Gruesome
Stock price: 89.73
P/E ratio: 28.593842248738106
Shares outstanding: 96971142
Book value: 8801134000
P/B ratio: 0.9886476642282689
Market cap (USD): 8701220571.66
Debt to equity: 0.1249503757129479
Effective tax rate (%): 23.73325206680392
COGS to revenue (%): 0
SG&A to revenue (%): 32.28825223951321
Free cash flow (dilution-adjusted): 41843000
Buyback yield (%): 0.001114786129154459
Retained earnings: 2240470000
Capitalized R&D asset: 0
FCF margin (%): 6.294404789662512
Revenue growth (%): 5.412005359677151
Rule of 40 score: 11.706410149339664
Financial ratios for SSB — quarterly report dated 2025-09-30
Total revenue: 698783000
Net income: 246641000
Capital expenditures: 20695000
Operating cash flow: 122442000
Depreciation & amortization: 41148000
Net tangible assets: 5422686000
Owner earnings: 267094000
Return on net tangible assets (%): 4.925492643313664
Buffett classification: The Gruesome
Stock price: 97.04
P/E ratio: 17.079889316864662
Shares outstanding: 96971142
Book value: 9011126000
P/B ratio: 1.0442734481439944
Market cap (USD): 9410079619.68
Debt to equity: 0.07728545799936656
Effective tax rate (%): 23.249915981030384
COGS to revenue (%): 0
SG&A to revenue (%): 31.398731795135255
Free cash flow (dilution-adjusted): 92187000
Buyback yield (%): 0.45727562081417633
Retained earnings: 2426463000
Capitalized R&D asset: 0
FCF margin (%): 13.192507545260831
Revenue growth (%): 5.11729708994908
Rule of 40 score: 18.30980463520991
Financial ratios for SSB — annual report dated 2025-12-31
Total revenue: 2617346000
Net income: 798667000
Capital expenditures: 69258000
Operating cash flow: 300846000
Depreciation & amortization: 157595000
Net tangible assets: 5494691000
Owner earnings: 887004000
Return on net tangible assets (%): 16.142927782472206
Buffett classification: The Gruesome
Stock price: 93
P/E ratio: 11.291710069403145
Shares outstanding: 96971142
Book value: 9059108000
P/B ratio: 0.9954971511543963
Market cap (USD): 9018316206
Debt to equity: 0.07574984203742796
Effective tax rate (%): 23.220599686601744
COGS to revenue (%): 0
SG&A to revenue (%): 33.976936942994925
Free cash flow (dilution-adjusted): 193586000
Buyback yield (%): 2.6149005492079107
Retained earnings: 2614173000
Capitalized R&D asset: 0
FCF margin (%): 7.3962708789743505
Revenue growth (%): 56.99702063005246
Rule of 40 score: 64.39329150902681
Financial ratios for SSB — quarterly report dated 2025-12-31
Total revenue: 623163000
Net income: 247722000
Capital expenditures: 16602000
Operating cash flow: 232055000
Depreciation & amortization: 41446000
Net tangible assets: 5494691000
Owner earnings: 272566000
Return on net tangible assets (%): 4.960533722460463
Buffett classification: The Gruesome
Stock price: 93
P/E ratio: 11.291710069403145
Shares outstanding: 96971142
Book value: 9059108000
P/B ratio: 0.9954971511543963
Market cap (USD): 9018316206
Debt to equity: 0.07574984203742796
Effective tax rate (%): 21.45982346674783
COGS to revenue (%): 0
SG&A to revenue (%): 37.2602352835454
Free cash flow (dilution-adjusted): 206892000
Buyback yield (%): 2.012759320628328
Retained earnings: 2614173000
Capitalized R&D asset: 0
FCF margin (%): 33.20030232860423
Revenue growth (%): -10.821671391547877
Rule of 40 score: 22.378630937056354
Financial ratios for SUNPHARMA.NS — annual report dated 2022-03-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 11.572464723724119
Shares outstanding: 2399334970
Market cap (USD): 27766219300.722668
Buyback yield (%): 0
Retained earnings: 4964479757.351972
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SUNPHARMA.NS — annual report dated 2023-03-31
Total revenue: 5271482338.61145
Gross profit: 3816863580.998782
Operating income: 1130007308.1607797
Net income: 1036898903.7758832
Capital expenditures: 251470158.34348357
Operating cash flow: 604059683.313033
Depreciation & amortization: 308213154.6894032
Net tangible assets: 4666322777.101096
Owner earnings: 1093641900.1218028
Return on net tangible assets (%): 23.436910654543624
Capex to operating income (%): 22.253852389041707
Buffett classification: The Great
Stock price: 11.6115712545676
P/E ratio: 26.868626118012102
Shares outstanding: 2399334970
Book value: 7224783191.230207
P/B ratio: 3.8561778575651506
Market cap (USD): 27860048967.730816
Debt to equity: 0.11608893936101325
Current ratio: 2.003483196865424
Quick ratio: 1.4753749937208016
Effective tax rate (%): 9.008835693096511
Interest coverage ratio: 53.938139534883724
COGS to revenue (%): 27.594112323172947
SG&A to revenue (%): 18.588054632664853
Free cash flow (dilution-adjusted): 350030450.6699148
Buyback yield (%): 0
Retained earnings: 5311845310.596833
Inventory turnover: 1.135961495474672
Receivables turnover: 3.7836108024559145
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 15.249638416617373
FCF margin (%): 6.640076323619355
Rule of 40 score: 6.640076323619355
Financial ratios for SUNPHARMA.NS — annual report dated 2024-03-31
Total revenue: 5727119558.700084
Gross profit: 4279744573.689891
Operating income: 1255309989.207339
Net income: 1152419954.430987
Capital expenditures: 260339369.22892433
Operating cash flow: 1455208058.5202062
Depreciation & amortization: 306606307.71075666
Net tangible assets: 5559991605.708118
Owner earnings: 1198686892.9128194
Return on net tangible assets (%): 21.55914932825074
Capex to operating income (%): 20.739050231992074
Buffett classification: The Great
Stock price: 19.02591170825336
P/E ratio: 39.61189245485116
Shares outstanding: 2399334970
Book value: 8049639045.449095
P/B ratio: 5.671004008999997
Market cap (USD): 45649535297.74473
Debt to equity: 0.04876907496565411
Current ratio: 2.559700666493959
Quick ratio: 1.9786798473893692
Effective tax rate (%): 12.982181461035418
Interest coverage ratio: 43.89663270013
COGS to revenue (%): 25.272302597760188
SG&A to revenue (%): 19.300040097616233
Free cash flow (dilution-adjusted): 1191170404.1251948
Buyback yield (%): 0.020329865806447172
Retained earnings: 6014456169.804533
Inventory turnover: 1.2230751224376262
Receivables turnover: 4.245433299820345
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 15.278394226102948
FCF margin (%): 20.798769641812076
Revenue growth (%): 8.64343633955249
Rule of 40 score: 29.442205981364566
Financial ratios for SUNPHARMA.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 6079228380.315337
Buffett classification: The Gruesome
Stock price: 22.59436215957955
Shares outstanding: 2399334970
Book value: 8287105828.953655
P/B ratio: 6.541661754206024
Market cap (USD): 54211443254.32394
Debt to equity: 0.03707066841645929
Current ratio: 2.6719711484408775
Quick ratio: 2.0961656820370878
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SUNPHARMA.NS — quarterly report dated 2024-12-31
Total revenue: 1566259470.8007925
Gross profit: 1246811982.748572
Operating income: 415177759.64564633
Net income: 339547732.83599484
Capital expenditures: 0
Depreciation & amortization: 73500407.97295721
Owner earnings: 413048140.80895203
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 21.58736449469635
P/E ratio: 38.13552082180962
Shares outstanding: 2399334970
Market cap (USD): 51795318542.26133
Effective tax rate (%): 16.07582556667817
Interest coverage ratio: 69.14793244030285
COGS to revenue (%): 20.39556625243545
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SUNPHARMA.NS — quarterly report dated 2025-03-31
Total revenue: 1498197334.5803132
Gross profit: 1189898293.1961656
Operating income: 322779985.9714753
Net income: 251803834.46340892
Capital expenditures: 0
Depreciation & amortization: 77599953.2382511
Net tangible assets: 6343004442.366144
Owner earnings: 329403787.70166004
Return on net tangible assets (%): 5.193182358528853
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 19.994865211810012
P/E ratio: 47.63070767504899
Shares outstanding: 2399334970
Book value: 8473924479.775543
P/B ratio: 5.661412187190387
Market cap (USD): 47974379323.13222
Debt to equity: 0.032588246411890856
Current ratio: 2.892374552124
Quick ratio: 2.3293751143907873
Effective tax rate (%): 33.60763286063269
Interest coverage ratio: 56.18762718762719
COGS to revenue (%): 20.57799959112268
Buyback yield (%): 0
Retained earnings: 6764302080.897825
Inventory turnover: 0.25745436298547447
Receivables turnover: 0.9823295986313162
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.7358890715374056
Revenue growth (%): -4.3455211278422885
Rule of 40 score: -4.3455211278422885
Financial ratios for SUNPHARMA.NS — annual report dated 2025-03-31
Total revenue: 6083849660.97732
Gross profit: 4657907411.737199
Operating income: 1470797287.8185644
Net income: 1281827215.3378534
Capital expenditures: 241707972.87818563
Operating cash flow: 1645088847.3228898
Depreciation & amortization: 301074351.18073416
Net tangible assets: 6343004442.366144
Owner earnings: 1341193593.6404018
Return on net tangible assets (%): 21.144453008456253
Capex to operating income (%): 16.433805996248367
Buffett classification: The Great
Stock price: 19.994865211810012
P/E ratio: 37.42655698762608
Shares outstanding: 2399334970
Book value: 8473924479.775543
P/B ratio: 5.661412187190387
Market cap (USD): 47974379323.13222
Debt to equity: 0.032588246411890856
Current ratio: 2.892374552124
Quick ratio: 2.3293751143907873
Effective tax rate (%): 20.157095664453436
Interest coverage ratio: 54.37932226832642
COGS to revenue (%): 23.438157231042684
SG&A to revenue (%): 19.79285662815555
Free cash flow (dilution-adjusted): 1396248538.695347
Buyback yield (%): 0.7066378941747284
Retained earnings: 6764302080.897825
Inventory turnover: 1.1907758512124473
Receivables turnover: 3.989024314527472
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 17.02316052053429
FCF margin (%): 22.9500828669565
Revenue growth (%): 6.228787414352582
Rule of 40 score: 29.17887028130908
Financial ratios for SUNPHARMA.NS — quarterly report dated 2025-06-30
Total revenue: 1613160542.9440675
Gross profit: 1283794757.7814183
Operating income: 394578750.29253453
Net income: 268297449.0989937
Capital expenditures: 0
Depreciation & amortization: 81974022.9347063
Owner earnings: 350271472.0337
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 19.366838286917858
P/E ratio: 54.05407494656156
Shares outstanding: 2399334970
Market cap (USD): 46467532360.13691
Effective tax rate (%): 27.425561890713794
Interest coverage ratio: 45.081149732620325
COGS to revenue (%): 20.417421353583727
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): 7.673435648980023
Rule of 40 score: 7.673435648980023
Financial ratios for SUNPHARMA.NS — quarterly report dated 2025-12-31
Total revenue: 1723189261.4459174
Gross profit: 1395117522.5576475
Operating income: 452516430.8789128
Net income: 376648100.7017935
Capital expenditures: 0
Depreciation & amortization: 81578478.333519
Owner earnings: 458226579.0353125
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 18.983402027403365
P/E ratio: 36.841904509776974
Shares outstanding: 2399334970
Market cap (USD): 45547540333.91779
Effective tax rate (%): 19.541961979201165
Interest coverage ratio: 51.840735068912714
COGS to revenue (%): 19.038636453258018
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): 6.820692396867338
Rule of 40 score: 6.820692396867338
Financial ratios for TAU.V — annual report dated 2022-02-28
Gross profit: -10446.875
Capital expenditures: 257137.5
Buffett classification: The Gruesome
Stock price: 0.8750000000000001
Shares outstanding: 278948529
Market cap (USD): 244079962.87500003
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for TAU.V — annual report dated 2023-02-28
Total revenue: 0
Operating income: -2858053.676470588
Net income: -3577071.3235294116
Capital expenditures: 296477.94117647054
Operating cash flow: -7272280.882352941
Net tangible assets: 83620621.3235294
Owner earnings: -3873549.264705882
Return on net tangible assets (%): -4.632289503947912
Buffett classification: The Gruesome
Stock price: 0.27205882352941174
Shares outstanding: 278948529
Book value: 83620621.3235294
P/B ratio: 0.9075561437337196
Market cap (USD): 75890408.625
Debt to equity: 0.0010132773592427177
Current ratio: 19.162927275406496
Quick ratio: 19.162927275406496
Effective tax rate (%): 1260.2539060170907
Free cash flow (dilution-adjusted): -7800206.617647058
Buyback yield (%): 0
Retained earnings: -22454386.76470588
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -3.032622865544469
Rule of 40 score: 0
Financial ratios for TAU.V — annual report dated 2024-02-29
Total revenue: 0
Operating income: -3202955.147058823
Net income: 653347.0588235294
Capital expenditures: 0
Operating cash flow: 3290594.117647059
Net tangible assets: 119309313.97058822
Owner earnings: 653347.0588235294
Return on net tangible assets (%): 0.5476077575842826
Buffett classification: The Gruesome
Stock price: 0.29411764705882354
P/E ratio: 125.57443075925778
Shares outstanding: 278948529
Book value: 119309313.97058824
P/B ratio: 0.687655324379999
Market cap (USD): 82043685
Debt to equity: 0.0001820219314148388
Current ratio: 2.9282075985108302
Quick ratio: 2.9282075985108302
Effective tax rate (%): 54.64391559616918
Free cash flow (dilution-adjusted): 3219858.8235294116
Buyback yield (%): 0
Retained earnings: -21801039.70588235
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -2.4294539645886095
Rule of 40 score: 0
Financial ratios for TAU.V — quarterly report dated 2024-11-30
Total revenue: 0
Gross profit: 0
Operating income: -622102.8571428572
Net income: -108599.28571428572
Capital expenditures: 0
Operating cash flow: -124280.00000000001
Depreciation & amortization: 0
Net tangible assets: 125607758.57142858
Owner earnings: -108599.28571428572
Return on net tangible assets (%): -0.08645905869941087
Buffett classification: The Gruesome
Stock price: 0.4428571428571429
Shares outstanding: 278948529
Book value: 125607758.57142857
P/B ratio: 0.9834929781578212
Market cap (USD): 123534348.55714287
Debt to equity: 0
Current ratio: 4.477401909261079
Quick ratio: 4.477401909261079
Effective tax rate (%): 120.44400519036958
Free cash flow (dilution-adjusted): -124280.00000000001
Buyback yield (%): 0
Retained earnings: -21732210.714285716
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -0.44519206306766246
Rule of 40 score: 0
Financial ratios for TAU.V — annual report dated 2025-02-28
Total revenue: 0
Gross profit: -65496.52777777778
Operating income: -3594485.416666667
Net income: -1146000.6944444445
Capital expenditures: 0
Operating cash flow: -5089406.25
Depreciation & amortization: 65496.52777777778
Net tangible assets: 127994088.8888889
Owner earnings: -1080504.1666666667
Return on net tangible assets (%): -0.8441828650420315
Buffett classification: The Gruesome
Stock price: 0.5694444444444444
Shares outstanding: 278948529
Book value: 127994088.8888889
P/B ratio: 1.2410392659843317
Market cap (USD): 158845690.125
Debt to equity: 0.005274885524227334
Current ratio: 6.7038025637089635
Quick ratio: 6.7038025637089635
Effective tax rate (%): 279.3562810635035
Interest coverage ratio: -277.2393679700054
Free cash flow (dilution-adjusted): -5854607.638888889
Buyback yield (%): 0
Retained earnings: -21735871.52777778
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -2.532452710666412
Rule of 40 score: 0